Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $175,865 - $355,037
66,115 Added 150.24%
110,121 $465,000
Q2 2022

Aug 15, 2022

SELL
$2.3 - $6.29 $144,088 - $394,049
-62,647 Reduced 58.74%
44,006 $123,000
Q1 2022

May 16, 2022

SELL
$4.63 - $9.94 $408,463 - $876,916
-88,221 Reduced 45.27%
106,653 $610,000
Q4 2021

Feb 14, 2022

BUY
$8.35 - $12.6 $1.63 Million - $2.46 Million
194,874 New
194,874 $1.78 Million
Q2 2021

Aug 16, 2021

SELL
$13.27 - $18.48 $685,926 - $955,231
-51,690 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$14.49 - $20.72 $748,988 - $1.07 Million
51,690 New
51,690 $838,000
Q3 2020

Nov 16, 2020

SELL
$13.67 - $17.77 $1.15 Million - $1.49 Million
-84,039 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.89 - $21.47 $915,184 - $1.8 Million
84,039 New
84,039 $1.24 Million
Q1 2018

May 15, 2018

SELL
$18.43 - $28.8 $1.51 Million - $2.36 Million
-81,951 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$14.8 - $18.85 $907,373 - $1.16 Million
61,309 Added 297.01%
81,951 $1.48 Million
Q3 2017

Nov 14, 2017

BUY
$14.65 - $16.85 $302,405 - $347,817
20,642
20,642 $333,000

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $227M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.